Page 13 - அட்லஸ் துணிகர News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அட்லஸ் துணிகர. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அட்லஸ் துணிகர Today - Breaking & Trending Today

Q32 Bio Appoints Dr. Jason Campagna as Chief Medical Officer

Share this article
Share this article
CAMBRIDGE, Mass., March 9, 2021 /PRNewswire/ Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna, M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team during a critical growth and development period for the company.
We are delighted to welcome Jason to Q32 Bio as our Chief Medical Officer, said Mike Broxson, Chief Executive Officer of Q32 Bio. Jason provided critical guidance in the early days of the company, serving as a trusted clinical counselor as we ve advanced our groundbreaking tissue-targeted complement program ADX-097 towards the clinic. His extensive experience leading clinical development programs and strong background in academic research will complement our leadership team in our mission to restore immune homeostasis in patie ....

United States , United Kingdom , Jason Campagna , Mike Broxson , Medicines Company , Bio Inc , Program At Intercept , Intercept Pharmaceuticals , Atlas Venture , University Of Miami , Critical Care At Harvard Medical School , University Of Pennsylvania , Health Science Lead Of Surgery , Neuroplasticty Research Group , Cottage Health System , Chief Medical , Chief Medical Officer , Chief Executive Officer , Primary Biliary Cholangitis , Non Alcoholic Steatohepatitis , Senior Vice President , Health Science Lead , Chief Medical Quality Officer , Massachusetts General , Cellular Pharmacology , Critical Care ,

Quench Bio hit by 'successful failure,' winds down ops in Twitter thread as tech sold off at auction

(GH01/ iStock)
Quench Bio’s short journey has come to an end after the biotech startup found that its target was simply undruggable.
The Cambridge, Massachusetts-based biotech had focused on blocking the gasdermin D protein with oral inhibitors to treat inflammatory diseases and had attempted to seek out a potent, selective chemical series to progress by the first quarter of 2021.
It has not, however, managed to hit that goal, and, with credit to the company, it is not trying to spin out this failure, but says it now simply recommends “to wind down and return capital to investors.” It raised $50 million last year from the likes of RA Capital, AbbVie Ventures, Atlas Venture and Arix Bioscience, and was a 2020 Fierce 15 winner. ....

United States , United Kingdom , Mike Nolan , Arix Bioscience , Eli Lilly , Mark Tebbe , Samantha Truex , Paraza Pharma , Iain Kilty , Atlas Venture , Clinical Collaborative Research Organization , Bristol Myers Squibb , Quench Bio , Abbvie Ventures , Life Science Cares Boston , Padlock Therapeutics , Chief Technology Officer Mark Tebbe , Senior Director , Biology Mike Nolan , Big Pharma , Scientific Officer Iain Kilty , Fierce 15 , Failed Drug Program , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , மைக் நோலன் ,

Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

Published: Feb 24, 2021
Feb. 24, 2021 11:00 UTC
Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors
Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic
Two investigational new drug (IND) applications planned in 2021
Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the successful closing of a $95 million Series C financing. Proceeds from the financing will be used to advance Xilio’s lead therapeutic candidates, XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4 mAb), into clinical trials. Investigational new drug (IND) applications for XTX202 and XTX101 are expected to be filed with the U.S. Food and Drug Administration (FDA) in 2021. ....

Dave Gardner , Rene Russo , Martin Huber , Bain Capital Life Sciences , Sv Health Investors , Atlas Venture , Drug Administration , Ventures Fund , Deerfield Management Company , Rock Springs Capital , Takeda Ventures , Rivervest Venture Partners , Andrew Hack , Xilio Therapeutics Board , Rock Springs , Xilio Therapeutics Raises 95 Million In Seriesc Financing To Advance Potent Tumor Selective Immuno Oncology Pipeline , டேவ் கார்ட்னர் , ரெனே ருஸ்ஸோ , மார்டின் ஹ்யூபர் , பைன் மூலதனம் வாழ்க்கை அறிவியல் , ஸ்வ் ஆரோக்கியம் முதலீட்டாளர்கள் , அட்லஸ் துணிகர , முயற்சிகள் நிதி , தீர்ப்பியல்ட் மேலாண்மை நிறுவனம் , பாறை நீரூற்றுகள் மூலதனம் , டாகேடா முயற்சிகள் ,

Xilio raises $95M to take twists on Yervoy and IL-2 into clinic

Xilio plans to file INDs for its two lead candidates this year. (PDPics/Pixabay)
Xilio Therapeutics has raised $95 million to take IL-2 and CTLA-4 immunotherapies into clinical trials. The series C positions Xilio to provide early clinical validation of anti-cancer agents that are designed to remain inactive until they reach tumors.
Immuno-oncology drugs are typically given systemically, causing them to trigger immune responses that affect healthy and cancerous tissues alike. The resulting adverse events are unpleasant and can prevent physicians from administering the most efficacious dose. Patients suffer from both the side effects and worse outcomes due to the use of suboptimal doses. ....

Bristol Myers Squibb Yervoy , Martin Huber , Bain Capital Life Sciences , Sv Health Investors , Atlas Venture , Thomas Jefferson University , Xilio Therapeutics , Akrevia Therapeutics , Translational Insights Key , Successful First In Human , Metabolite Based Biomarker Discovery , Springs Capital , Deerfield Management , Existing Xilio , Takeda Ventures , Bristol Myers Squibb , Series C , Rock Spring Ventures , Venture Capital Vc , Immuno Oncology , மார்டின் ஹ்யூபர் , பைன் மூலதனம் வாழ்க்கை அறிவியல் , ஸ்வ் ஆரோக்கியம் முதலீட்டாளர்கள் , அட்லஸ் துணிகர , தாமஸ் ஜெஃபர்சன் பல்கலைக்கழகம் , மொழிபெயர்ப்பு நுண்ணறிவு விசை ,

Future Founders Initiative aims to increase female entrepreneurship in biotech

Caption:
The Future Founders Initiative aims to increase the fraction of MIT female faculty who found companies from less than 10 percent to 25 percent by 2024.
Caption:
Future Founders collaborators (clockwise from top left) Susan Hockfield, MIT president emerita; Harvey Lodish, professor of biology and biomedical engineering; and Sangeeta Bhatia, the John and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science.
Previous image
Next image
The gender disparity in biotech really got Sangeeta Bhatia’s attention while she was on sabbatical. Bhatia had taken a year to focus on her startup biotech company, Glympse Bio. The startup, inspired by bioengineering breakthroughs in Bhatia’s lab at MIT, advances biosensing technology and is now well-funded. But in 2018, Bhatia had to do what all startup founders have to do pitch ideas and court ....

Harvard University , United States , Jodi Cook , Susan Hockfield , Glympse Bio , Ron Bartek , Theresia Gouw , Jackie Grant , Peter Barrett , Angela Koehler , Amy Schulman , Carolyn Bertozzi , Tanja Konig , Maria Zuber , Anantha Chandrakesan , Jay Bradner , Anantha Chandrakasan , Harvey Lodish , Daphne Koller , Sangeeta Bhatia , Russ Wilcox , Kronos Bio , Nancy Hopkins , Aoife Brennan , Simmons University Business School , Institute For Medical Engineering ,